These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers. Bian Y; Meng J; Ma S; Li G; Wang Y; Li S; Liu L; Huang C; Zhang H; Zhong D; Miao L Br J Clin Pharmacol; 2022 Jul; 88(7):3307-3320. PubMed ID: 35112382 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects. Darwish M; Nunez R; Youakim JM; Robertson P Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349 [TBL] [Abstract][Full Text] [Related]
9. Mass balance, metabolic disposition, and pharmacokinetics of [ Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566 [TBL] [Abstract][Full Text] [Related]
10. Biotransformation of [ Pusalkar S; Plesescu M; Gupta N; Hanley M; Venkatakrishnan K; Wu JT; Xia C; Zhang X; Chowdhury S Cancer Chemother Pharmacol; 2018 Nov; 82(5):803-814. PubMed ID: 30128949 [TBL] [Abstract][Full Text] [Related]
11. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors. Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109 [TBL] [Abstract][Full Text] [Related]
12. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers. Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600 [TBL] [Abstract][Full Text] [Related]
13. Human Mass Balance and Metabolite Profiling of [ Mu S; Palmer D; Fitzgerald R; Andreu-Vieyra C; Zhang H; Tang Z; Su D; Sahasranaman S Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1108-1120. PubMed ID: 33876576 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, absorption, metabolism, and excretion of [ Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648 [TBL] [Abstract][Full Text] [Related]
15. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [ Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928 [TBL] [Abstract][Full Text] [Related]
16. Biotransformation Pathways and Metabolite Profiles of Oral [ Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Dubbelman AC; Rosing H; Darwish M; D'Andrea D; Bond M; Hellriegel E; Robertson P; Beijnen JH; Schellens JH Drugs R D; 2013 Mar; 13(1):17-28. PubMed ID: 23322528 [TBL] [Abstract][Full Text] [Related]
18. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410 [TBL] [Abstract][Full Text] [Related]
19. Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [ Guo F; Liu B; Li X; Wang H; Zhu X; Su Y; He C; Zhu M; Ding J; Xu Y; Zhao X; Wang Y; Shan R; Zhu J; Xie J; Ge Q; Fan L; Ding Y; Xie Y; Zhang C; Li H; Wang H; Zhou H Cancer Chemother Pharmacol; 2023 Feb; 91(2):143-156. PubMed ID: 36572783 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies. Calvo E; Reddy G; Boni V; García-Cañamaque L; Song T; Tjornelund J; Choi MR; Allen LF Invest New Drugs; 2016 Apr; 34(2):193-201. PubMed ID: 26769244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]